...
机译:HR-NBL1 / SIOPEN试验随机化剂量减少皮下白细胞介素2(SCIL2)的早期结果与高危神经母细胞瘤患者的DINOUTUXIMABβ(DB)长期输注(LTI)
St Anna Childrens Hosp Vienna Austria;
St Anna Kinderkrebsforsch Childrens Canc Res Inst Studies &
Stat Integrated Res &
Projects;
Gustave Roussy Children &
Adolescent Oncol Dept Paris France;
Univ Hosp Southampton NHS Fdn Trust Southampton Hants England;
Fdn IRCCS Ist Nazl Tumori Paediat Haematol &
Oncol Milan Italy;
Jagiellonia Univ Coll Med Paediat Haematol Oncol Krakow Poland;
Hosp Univ &
Politecn La Fe Paediat Haematol &
Oncol Valencia Spain;
Tel Aviv Univ Sackler Fac Med Schneider Childrens Med Ctr Israel Paediat Haemaotol &
Oncol;
Univ Hosp Lausanne Paediat Haematol &
Oncol Lausanne Switzerland;
Ghent Univ Hosp Paediat Haematol &
Oncol Ghent Belgium;
Univ Hong Kong Queen Mary Hosp Dept Pediat &
Adolescent Med Hong Kong Peoples R China;
Natl Hosp Norway Paediat Haematol &
Oncol Oslo Norway;
Univ Helsinki Univ Tampere Hosp Children &
Adolescents Div Hematol Oncol &
Stem Cell;
Our Ladys Childrens Hosp Crumlin Pediat Haematol Oncol Dublin Ireland;
Univ Hosp Aarhus Paediat Haematol &
Oncol Aarhus Denmark;
Apeiron Biol AG Ceo Vienna Austria;
Med Univ Vienna St Anna Kinderkrebsforsch CCRI Dept Paediat Vienna Austria;
Paris Descartes Univ Necker Enfants Malad Hosp Dept Pediat Surg Paris France;
Ghent Univ Hosp Paediat Haematol &
Oncol Ghent Belgium;
Univ Med Greifswald Pediat Hematol &
Oncol Greifswald Germany;
机译:HR-NBL1 / SIOPEN试验随机化剂量减少皮下白细胞介素2(SCIL2)的早期结果与高危神经母细胞瘤患者的DINOUTUXIMABβ(DB)长期输注(LTI)
机译:一种随机化和难治性高危神经母细胞瘤患者,治疗抗GD2抗体Dinutuximabβ的长期输注,有或没有皮下Interaleukin-2,Siopen研究
机译:白细胞介素2具有抗GD2抗体CH14.18 / CHO(DINUTUXIMABβ)高危神经母细胞瘤(HR-NBL1 / SIOPEN):多期,随机,第3阶段试验
机译:在基于SIOPEN的高危神经母细胞瘤1试验(HR-NBL1)中使用基于Dinutuximab Beta的免疫治疗的研究
机译:Dinutuximabβ的免疫治疗在Siopen高危神经母细胞瘤1试验中的作用调查(HR-NBL1)